Skip to main content
Top
Published in: Cancer Causes & Control 9/2018

01-09-2018 | Original paper

C-reactive protein concentration and risk of selected obesity-related cancers in the Women’s Health Initiative

Authors: Theodore M. Brasky, Geoffrey C. Kabat, Gloria Y. F. Ho, Cynthia A. Thomson, Wanda K. Nicholson, Wendy E. Barrington, Marisa A. Bittoni, Sylvia Wassertheil-Smoller, Thomas E. Rohan

Published in: Cancer Causes & Control | Issue 9/2018

Login to get access

Abstract

Background

Obesity is a chronic inflammatory condition strongly associated with the risk of numerous cancers. We examined the association between circulating high-sensitivity C-reactive protein (hsCRP), a biomarker of inflammation and strong correlate of obesity, and the risk of three understudied obesity-related cancers in postmenopausal women: ovarian cancer, kidney cancer, and multiple myeloma.

Methods

Participants were 24,205 postmenopausal women who had measurements of baseline serum hsCRP (mg/L) in the Women’s Health Initiative (WHI) CVD Biomarkers Cohort, a collection of four sub-studies within the WHI. Incident cancers were identified over 17.9 years of follow-up (n = 153 ovarian, n = 110 kidney, n = 137 multiple myeloma). hsCRP was categorized into study-specific quartiles. Adjusted Cox regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations of baseline hsCRP with the risk of these cancers.

Results

There was no clear association between baseline hsCRP concentration and the risk of ovarian cancer (quartile 4 vs. 1: HR 0.87, 95% CI 0.56–1.37), kidney cancer (HR 0.95, 95% CI 0.56–1.61), or multiple myeloma (HR 0.82, 95% CI 0.52–1.29). HRs for 1 mg/L increases in hsCRP also approximated the null value for each cancer.

Conclusions

The results of this study suggest that elevated CRP is not a major risk factor for these obesity-related cancers (ovarian or kidney cancers, or multiple myeloma) among postmenopausal women. Given the importance of elucidating the mechanisms underlying the association of obesity with cancer risk, further analysis with expanded biomarkers and in larger or pooled prospective cohorts is warranted.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Chaturvedi AK, Moore SC, Hildesheim A (2013) Invited commentary: circulating inflammation markers and cancer risk–implications for epidemiologic studies. Am J Epidemiol 177:14–19CrossRefPubMed Chaturvedi AK, Moore SC, Hildesheim A (2013) Invited commentary: circulating inflammation markers and cancer risk–implications for epidemiologic studies. Am J Epidemiol 177:14–19CrossRefPubMed
4.
go back to reference Brenner DR, Scherer D, Muir K et al (2014) A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomark Prev 23:1729–1751CrossRef Brenner DR, Scherer D, Muir K et al (2014) A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomark Prev 23:1729–1751CrossRef
5.
go back to reference Choi J, Joseph L, Pilote L (2013) Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 14:232–244CrossRefPubMed Choi J, Joseph L, Pilote L (2013) Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 14:232–244CrossRefPubMed
6.
go back to reference Heikkila K, Harris R, Lowe G et al (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20:15–26CrossRefPubMed Heikkila K, Harris R, Lowe G et al (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20:15–26CrossRefPubMed
7.
go back to reference Bittoni MA, Focht BC, Clinton SK, Buckworth J, Harris RE (2015) Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey. Int J Oncol 47:1537–1544CrossRefPubMed Bittoni MA, Focht BC, Clinton SK, Buckworth J, Harris RE (2015) Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey. Int J Oncol 47:1537–1544CrossRefPubMed
8.
go back to reference Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomark Prev 15:381–384CrossRef Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomark Prev 15:381–384CrossRef
9.
go back to reference Zeng F, Wei H, Yeoh E et al (2016) Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. Cancer Epidemiol Biomark Prev 25:1231–1239CrossRef Zeng F, Wei H, Yeoh E et al (2016) Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. Cancer Epidemiol Biomark Prev 25:1231–1239CrossRef
10.
go back to reference The Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 19:61–109CrossRef The Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 19:61–109CrossRef
12.
go back to reference Toriola AT, Cheng TY, Neuhouser ML et al (2013) Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 132:2648–2658CrossRefPubMed Toriola AT, Cheng TY, Neuhouser ML et al (2013) Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 132:2648–2658CrossRefPubMed
13.
go back to reference Wang T, Rohan TE, Gunter MJ et al (2011) A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomark Prev 20:971–977CrossRef Wang T, Rohan TE, Gunter MJ et al (2011) A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomark Prev 20:971–977CrossRef
14.
go back to reference Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K (2016) Body fatness and cancer–viewpoint of the IARC working group. N Engl J Med 375:794–798CrossRefPubMed Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K (2016) Body fatness and cancer–viewpoint of the IARC working group. N Engl J Med 375:794–798CrossRefPubMed
15.
go back to reference Anderson GL, Manson J, Wallace R et al (2003) Implementation of the Women’s Health Initiative study design. Ann Epidemiol 13:S5–S17CrossRefPubMed Anderson GL, Manson J, Wallace R et al (2003) Implementation of the Women’s Health Initiative study design. Ann Epidemiol 13:S5–S17CrossRefPubMed
16.
go back to reference Hays J, Hunt JR, Hubbell FA et al (2003) The Women’s Health Initiative recruitment methods and results. Ann Epidemiol 13:S18–S77CrossRefPubMed Hays J, Hunt JR, Hubbell FA et al (2003) The Women’s Health Initiative recruitment methods and results. Ann Epidemiol 13:S18–S77CrossRefPubMed
17.
go back to reference Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR (2003) The Women’s Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 13:S78–S86CrossRefPubMed Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR (2003) The Women’s Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 13:S78–S86CrossRefPubMed
18.
go back to reference Ritenbaugh C, Patterson RE, Chlebowski RT et al (2003) The Women’s Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol 13:S87–S97CrossRefPubMed Ritenbaugh C, Patterson RE, Chlebowski RT et al (2003) The Women’s Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol 13:S87–S97CrossRefPubMed
19.
go back to reference Jackson RD, LaCroix AZ, Cauley JA, McGowan J (2003) The Women’s Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol 13:S98–S106CrossRefPubMed Jackson RD, LaCroix AZ, Cauley JA, McGowan J (2003) The Women’s Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol 13:S98–S106CrossRefPubMed
20.
go back to reference Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M (2003) The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 13:S107–S121CrossRefPubMed Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M (2003) The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 13:S107–S121CrossRefPubMed
21.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
22.
go back to reference Peterson JI, Young DS (1968) Evaluation of the hexokinase-glucose-6-phosphate dehydrogenase method of determination of glucose in urine. Anal Biochem 23:301–316CrossRefPubMed Peterson JI, Young DS (1968) Evaluation of the hexokinase-glucose-6-phosphate dehydrogenase method of determination of glucose in urine. Anal Biochem 23:301–316CrossRefPubMed
23.
go back to reference Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239–241CrossRef Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239–241CrossRef
24.
go back to reference Birmann BM, Neuhouser ML, Rosner B et al (2012) Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood 120:4929–4937CrossRefPubMedPubMedCentral Birmann BM, Neuhouser ML, Rosner B et al (2012) Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood 120:4929–4937CrossRefPubMedPubMedCentral
25.
go back to reference Key TJ, Appleby PN, Allen NE, Reeves GK (2010) Pooling biomarker data from different studies of disease risk, with a focus on endogenous hormones. Cancer Epidemiol Biomark Prev 19:960–965CrossRef Key TJ, Appleby PN, Allen NE, Reeves GK (2010) Pooling biomarker data from different studies of disease risk, with a focus on endogenous hormones. Cancer Epidemiol Biomark Prev 19:960–965CrossRef
Metadata
Title
C-reactive protein concentration and risk of selected obesity-related cancers in the Women’s Health Initiative
Authors
Theodore M. Brasky
Geoffrey C. Kabat
Gloria Y. F. Ho
Cynthia A. Thomson
Wanda K. Nicholson
Wendy E. Barrington
Marisa A. Bittoni
Sylvia Wassertheil-Smoller
Thomas E. Rohan
Publication date
01-09-2018
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 9/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-018-1061-9

Other articles of this Issue 9/2018

Cancer Causes & Control 9/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine